Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive.
Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space Read More »
